Citations

Clear

6273 citation(s) found for "To, Andrew".

Creation and Validation of a Novel 3-Dimensional Pediatric Hip Ultrasound Model
Nichols, Francesca R. , Nguyen, Mylinh T., Ekpenyong, Atim, Pade, Kathryn , Skinner, John A. , Ryan, Justin , Skinner, John Andrew , Morris, Jonathan M. , Nguyen, Mylinh T.

Mayo Clinic

Pediatric Emergency Care | July 1, 2024 | Volume: 40 | Issue: 9 | Pages: e216-e220

10.1097/pec.0000000000003155 | PMID 38950383 Get It

Objectives The aim of this study was to create and validate a 3-dimensional (3D) ultrasound model with normal and abnormal pediatric hip joint anatomy that is comparable to a pediatric hip joint in appearance and anatomy and replicates sonographic characteristics of a pediatric hip joint. Methods A 3D rendering of the bone and soft tissue was created from a computed tomography pelvic scan of a pediatric patient. This rendering was modified to include a unilateral joint effusion. The bone was 3D printed with a photopolymer plastic, whereas the soft tissue was cast with a silicone mixture in a 3D-printed mold. The effusion was simulated by injecting saline into the soft tissue cavity surrounding the bone. The ultrasound model was validated by pediatric point-of-care ultrasonographers at an international pediatric ultrasound conference. Results A pediatric hip ultrasound model was developed that simulates both normal and abnormal pediatric hip joint anatomy, each with an appropriately sized, measurable joint effusion. Validation by pediatric point-of-care ultrasonographers showed that the key aspects of a normal pediatric hip joint (femoral physis, sloped femoral neck, and adequate soft tissue) with an identifiable and measurable effusion were included in the ultrasound model. Conclusions In this study, we successfully created a cost-effective, reusable, and reproducible 3D pediatric hip ultrasound model. The majority of pediatric point-of-care ultrasonographers who evaluated the model agreed that this model is comparable to a pediatric patient for the purpose of teaching ultrasound skills and joint space measurement.
Cannabis in combat sports: position statement of the Association of Ringside Physicians
Stellpflug, Samuel J. , Stolbach, Andrew , Ghorayeb, Joe , Magraken, Erik, Twohey, Eric , Lapoint, Jeff , deWeber, Kevin

Mayo Clinic

The Physician and Sportsmedicine | July 1, 2024 | Volume: 52 | Issue: 5 | Pages: 432-443

10.1080/00913847.2024.2375788 | PMID 38949963 Get It

Contemporary Issue: Health and Safety of Female Wrestlers
Moschelli, Jill S., Woodroffe, Lisa , Horswill, Craig A. , Bloomfield, Susan A. , Oppliger, Robert A., Jagim, Andrew R.

Mayo Clinic

Current Sports Medicine Reports | June 28, 2024 | Volume: 23 | Issue: 7 | Pages: 262-269

10.1249/jsr.0000000000001183 | PMID 38941548 Get It

Abstract Female wrestling has grown exponentially over the past decade. Within the United States, 46 states now recognize female high school wrestling, and 153 colleges have programs. It is on track to become an NCAA championship-level sport in 2026. A primary health and safety risk among this cohort pertains to rapid weight loss strategies. These can lead to intentional caloric restriction and decreased body fatness, with the perceived goal of attaining a competitive advantage. Low energy availability and low body fatness are associated with a number of health concerns including menstrual dysfunction and loss of bone mineral density in girls and women. The current recommendation of 12% as a minimum for percentage body fat is very likely too low, opening the door for health perturbations among this population. The minimum threshold might more appropriately fall within the range of 18% to 20%. Body fat assessment methods, primarily skinfold measures that are used to guide weight class selection, have not been adequately validated among this population and therefore should be an area of research focus, while also exploring alternative assessment techniques. Further, we recommend that weight cycling, restrictive energy intake, and intentional dehydration be avoided. Research should assess the effects of frequent weight cycling (to “make weight”) and prolonged periods of low body fat on the reproductive and bone health of these athletes. Finally, research and clinical evaluations on female wrestlers are limited, and we offer a list of research priorities for future investigation into this contemporary issue.
End-Stage Kidney Disease After Partial and Radical Nephrectomy Among Patients With Severe Chronic Kidney Disease
Khanna, Abhinav, Gottlich, Harrison C. , Dorr, Maddy, Lohse, Christine M. , Zganjar, Andrew , Sharma, Vidit , Potretzke, Aaron M. , Britton, Cameron J. , Boorjian, Stephen A. , Leibovich, Bradley C. , Thompson, R. Houston, Joyce, Daniel , Potretzke, Aaron, Britton, Cameron, Dorr, Maddy, Rule, Andrew D.

Mayo Clinic

Journal of Urology | June 27, 2024 | Volume: 212 | Issue: 4 | Pages: 550-559

10.1097/ju.0000000000004124 | PMID 38935793 Get It

Herpetic lymphadenitis mimicking Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma
Bidot, Samuel , Feldman, Andrew L. , Feldman, Andrew L

Mayo Clinic

Blood | June 27, 2024 | Volume: 143 | Issue: 26 | Pages: 2808-2808

10.1182/blood.2024024564 | PMID 38935358 Get It

Lung Transcriptomics Link Emphysema to Barrier Dysfunction and Macrophage Subpopulations
Lu, Robin, Gregory, Andrew , Suryadevara, Rahul , Jain, Dhawal , Morrow, Jarrett D. , Hobbs, Brian D. , Yun, Jeong H. , Lichtblau, Noah, Chase, Robert , Bartholmai, Brian J. , Silverman, Edwin K. , Morrow, Jarrett D , Hobbs, Brian D , Yun, Jeong H , Curtis, Jeffrey L , Hersh, Craig P , Boueiz, Adel , Bartholmai, Brian J , Xu, Zhonghui , Curtis, Jeffrey L. , Sauler, Maor , Hersh, Craig P. , Castaldi, Peter J. , Boueiz, Adel

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 27, 2024 | Volume: 211 | Issue: 1 | Pages: 75-90

10.1164/rccm.202305-0793oc | PMID 38935868 Get It

Abstract Rationale Although many studies have examined gene expression in lung tissue, the gene regulatory processes underlying emphysema are still not well understood. Finding efficient nonimaging screening methods and disease-modifying therapies has been challenging, but knowledge of the transcriptomic features of emphysema may help in this effort. Objectives Our goals were to identify emphysema-associated biological pathways through transcriptomic analysis of bulk lung tissue, to determine the lung cell types in which these emphysema-associated pathways are altered, and to detect unique and overlapping transcriptomic signatures in blood and lung samples. Methods Using RNA-sequencing data from 446 samples in the Lung Tissue Research Consortium and 3,606 blood samples from the COPDGene study, we examined the transcriptomic features of chest computed tomography–quantified emphysema. We also leveraged publicly available lung single-cell RNA-sequencing data to identify cell types showing chronic obstructive pulmonary disease–associated differential expression of the emphysema pathways found in the bulk analyses. Measurements and Main Results In the bulk lung RNA-sequencing analysis, 1,087 differentially expressed genes and 34 dysregulated pathways were significantly associated with emphysema. We observed alternative splicing of several genes and increased activity in pluripotency and cell barrier function pathways. Lung tissue and blood samples shared differentially expressed genes and biological pathways. Multiple lung cell types displayed dysregulation of epithelial barrier function pathways, and distinct pathway activities were observed among various macrophage subpopulations. Conclusions This study identified emphysema-related changes in gene expression and alternative splicing, cell type–specific dysregulated pathways, and instances of shared pathway dysregulation between blood and lung.
Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
French, Jena D. , Haugen, Bryan R. , Worden, Francis P. , Bowles, Daniel W. , Gianoukakis, Andrew G. , Konda, Bhavana , Dadu, Ramona , Sherman, Eric J. , McCue, Shaylene , Foster, Nathan R. , Farias, Ticiana D.J. , Norman, Paul J. , Wirth, Lori J. , Nikiforov, Yuri , Farias, Ticiana D J , Norman, Paul J , Wirth, Lori J , Bowles, Daniel W , Worden, Frank , Nikiforov, Yuri E.

Mayo Clinic

Clinical Cancer Research | June 26, 2024 | Volume: 30 | Issue: 17 | Pages: 3757-3767

10.1158/1078-0432.ccr-23-3417 | PMID 38922338 Get It

Abstract Purpose: Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting further therapy. We evaluated the efficacy and safety of lenvatinib plus pembrolizumab in these patients. Patients and Methods: We enrolled patients with progressive, RAI-refractory differentiated thyroid cancer who were either naïve to multikinase inhibitors (cohort 1) or who had progressed on lenvatinib (cohort 2). Patients received oral lenvatinib daily (cohort 1, 20 mg; cohort 2, dose at progression) and intravenous pembrolizumab (200 mg) every 21 days. Results: In cohorts 1 and 2, 30 and 27 patients were enrolled, respectively. Adverse events were consistent with those observed in other cancers. In cohort 1, the confirmed overall response rate was 65.5%. There were no complete responses (primary endpoint). The 12- and 18-month PFS were 72.0% and 58.0%, respectively, and the median PFS was 26.8 months. In cohort 2, the confirmed overall response rate was 16% (primary endpoint), and the median PFS was 10.0 months (95% confidence interval, 7.0–17.9 months). Tumor histology, driver mutations, and immune-related biomarkers, including PD-L1 expression, thyroid-specific antibody levels, and CD8+ T-cell tumor infiltrate, did not correlate with response to therapy. Increased baseline peripheral blood monocytes and neutrophil to lymphocyte ratio were associated with a worse PFS in cohort 1. Conclusions: Lenvatinib plus pembrolizumab may enhance the durability of lenvatinib monotherapy in lenvatinib-naïve patients. Furthermore, the addition of pembrolizumab may be a viable salvage therapy for patients who have progressed on lenvatinib.
A Novel Controlled Metabolic Accelerator for the Treatment of Obesity-Related Heart Failure with Preserved Ejection Fraction: Rationale and Design of the Phase 2a HuMAIN Trial
Kitzman, Dalane W. , Jorkasky, Diane K., Khan, Shaharyar M., Lewis, Gregory D. , Pandey, Ambarish , Borlaug, Barry A. , Sauer, Andrew J , Litwin, Sheldon E. , Sharma, Kavita, Shah, Sanjiv J

Mayo Clinic

European Journal of Heart Failure | June 26, 2024 | Volume: 26 | Issue: 9 | Pages: 2013-2024

10.1002/ejhf.3305 | PMID 38924328 Get It

Abstract Aims Compared with those without obesity, patients with obesity-related heart failure with preserved ejection fraction (HFpEF) have worse symptoms, haemodynamics, and outcomes. Current weight loss strategies (diet, drug, and surgical) work through decreased energy intake rather than increased expenditure and cause significant loss of skeletal muscle mass in addition to adipose tissue. This may have adverse implications for patients with HFpEF, who already have reduced skeletal muscle mass and function and high rates of physical frailty. Mitochondrial uncoupling agents may have unique beneficial effects by producing weight loss via increased catabolism rather than reduced caloric intake, thereby causing loss of adipose tissue while sparing skeletal muscle. HU6 is a controlled metabolic accelerator that is metabolized to the mitochondrial uncoupling agent 2,4-dinotrophenol. HU6 selectively increases carbon oxidation from fat and glucose while also decreasing toxic reactive oxygen species (ROS) production. In addition to sparing skeletal muscle loss, HU6 may have other benefits relevant to obesity-related HFpEF, including reduced specific tissue depots contributing to HFpEF; improved glucose utilization; and reduction in systemic inflammation via both decreased ROS production from mitochondria and decreased cytokine elaboration from excess, dysfunctional adipose. Methods We describe the rationale and design of HuMAIN-HFpEF, a Phase 2a randomized, double-blind, placebo-controlled, dose-titration, parallel-group trial in patients with obesity-related HFpEF to evaluate the effects of HU6 on weight loss, body composition, exercise capacity, cardiac structure and function, metabolism, and inflammation, and identify optimal dosage for future Phase 3 trials. Conclusions HuMAIN will test a promising novel agent for obesity-related HFpEF.
Editorial: Reading the cholate—A new gateway to portal hypertension and oesophageal varices: Authors' reply
Hassanein, Tarek , Keaveny, Andrew P. , Mantry, Parvez , Kittelson, John, Helmke, Steve M. , Everson, Gregory T. , Investigators, for the SHUNT‐V, McRae, Michael P , Everson, Gregory T , Keaveny, Andrew P , Smith, Alastair D. , McRae, Michael P. , Investigators, for the SHUNT‐V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | June 25, 2024 | Volume: 60 | Issue: 3 | Pages: 405-406

10.1111/apt.18128 | PMID 38924551 Get It

LINKED CONTENTThis article is linked to Hassanein et al papers. To view these articles, visit https://doi.org/10.1111/apt.18054 and https://doi.org/10.1111/apt.18113
Increased Pretransplant Inflammatory Biomarkers Predict Death With Function After Kidney Transplantation
Lorenz, Elizabeth C. , Liang, Yun , Dhala, Atiya , Kennedy, Cassie C. , Kennedy, Cassie C , Smith, Byron H. , Park, Walter D. , Bentall, Andrew , Waterman, Amy D , Hickson, LaTonya J. , Rule, Andrew D. , Cheville, Andrea , LeBrasseur, Nathan K. , Stegall, Mark D.

Mayo Clinic

Transplantation | June 24, 2024 | Volume: 108 | Issue: 12 | Pages: 2434-2445

10.1097/tp.0000000000005103 | PMID 38913783 Get It

Background. Chronic systemic inflammation is associated with mortality in patients with chronic kidney disease, cardiovascular disease, and diabetes. The goal of this study was to examine the relationship between pretransplant inflammatory biomarkers (growth differentiation factor-15 [GDF-15], interleukin-6 [IL-6], soluble tumor necrosis factor receptor-1, monokine induced by gamma interferon/chemokine [C-X-C motif] ligand 9 [MIG/CXCL9], monocyte chemoattractant protein-1, soluble FAS, tumor necrosis factor-α, interleukin-15, and interleukin-1β) and death with function (DWF) after kidney transplantation (KT). Methods. We retrospectively measured inflammatory biomarker levels in serum collected up to 1 y before KT (time from blood draw to KT was 130 ± 110 d) in recipients transplanted between January 2006 and December 2018. Kaplan-Meier estimation, Cox regression, and Gradient Boosting Machine modeling were used to examine the relationship between inflammatory biomarkers and DWF. Results. Our cohort consisted of 1595 KT recipients, of whom 62.9% were male and 83.2% were non-Hispanic White. Over a mean follow-up of 7.4 ± 3.9 y, 21.2% of patients (n = 338) experienced DWF. Patients with the highest quartile levels of GDF-15 (>4766 pg/mL), IL-6 (>6.11 pg/mL), and MIG/CXCL9 (> 5835 pg/mL) had increased rates of DWF, and each predicted mortality independently of the others. When adjusted for clinical factors (age, diabetes, etc), the highest quartile levels of GDF-15 and IL-6 remained independently associated with DWF. Adding inflammatory markers to a clinical Cox model improved the C-statistic for DWF from 0.727 to 0.762 using a Gradient Boosting Machine modeling approach. Conclusions. These findings suggest that pre-KT serum concentrations of GDF-15, IL-6, and MIG/CXCL9 may help to risk stratify and manage patients undergoing KT and suggests that chronic inflammation may play a role in mortality in KT recipients.